Table 1.

Characteristics of the Patients and Isolates

Patient	Age in years	Sex	Hospitalization dates	Diagnosis	Location (unit, hospital)	Isolate	Specimen	Isolation date	Colistin therapy, days/DDD	MIC, μg/mL	Sequence type	KPC	PFGE	Outcome
A	63	Male	13 Jan 2010–10 Mar 2010	Cholangitis, OLTx	Surgical, A	A1	Urine	22 Jan 2010	None	1	258	2	A1	Survived
					TICU, A	A2	Wound	10 Mar 2010	14/19.2	>128	258	2	A1
B	25	Female	18 Jan 2010–18 Sep 2010	Hemorrhagic pancreatitis,  multivisceral Tx	TICU, A	B1	Blood	20 Mar 2010	None	1	258	2	A1	Survived
					TICU, A	B2	Wound	13 Apr 2010	18/48.3	>128	258	2	A1
C	65	Male	11 Mar 2010–18 Mar 2010,  20 Mar 10–21 Apr 2010	Cholangitis, OLTx	Surgical, A	C	Blood	20 Mar 2010	None	>128	258	2	A1	Survived
D	42	Male	25 Feb 2010–23 May 2010	Intra-abdominal  abscess, OLTx	TICU, A	D1	Blood	3 Apr 2010	None	1	258	2	A1	Died
					TICU, A	D2	Blood	17 Apr 2010	12/27.6	128	258	2	A1
E	41	Female	22 Mar 2010–25 Mar 2010,  16 May 2010–20 May 2010	TBI, UTI	Medicine, B	E	Urine	16 May 2010	None	128	258	2	A2	Survived

NOTE. MIC, minimum inhibitory concentration; OLTx, orthotopic liver transplantation; Tx, transplantation; TBI, traumatic brain injury; TICU, transplant ICU; DDD, defined daily dose; ST, multilocus sequence type; PFGE, pulse-field gel electrophoresis. The study patients were located in the same units during the following periods of time:

-A + B: 1/18/10–1/20/10, 2/22/10–2/27/10

-A + B + D: 2/25/10–2/27/10

-B + D: 2/27/10–3/1/10, 3/4/10–3/10/10, 3/16/10–3/17/10, 4/5/10–5/17/10

-A + D: 3/1/10–3/4/10

-B + C: 3/12/10–3/14/10, 3/22/10–3/27/10, 3/28/10–3/30/10

-C + D: 3/14/10–3/18/10, 3/20/10–3/22/10, 3/27/10–3/28/10

-B + C + D: 3/30/10–4/5/10